Phase 1/2 AlphaBet Trial: Promising Combination of Lutetium-177 PSMA-I&T and Radium-223 in Advanced Prostate Cancer

/in , , , /by

A novel therapeutic approach combining lutetium-177 177Lu-PSMA-I&T and radium-223 (223Ra) shows encouraging results for men with metastatic castration-resistant prostate cancer (mCRPC), as demonstrated in the recently reported AlphaBet trial published in The Lancet Oncology in October 2025. This phase 1/2 AlphaBet study is the first to evaluate the safety, feasibility, and preliminary efficacy of the […]

Read more

Real-World ARON-3 Data Highlight the Advantage of Triplet Therapy in High-Volume mHSPC

/in /by

At the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin,  pivotal real-world data from the international ARON-3 study were revealed, advancing treatment insights for high-volume metastatic hormone-sensitive prostate cancer (mHSPC) with bone metastases. The ARON-3 study evaluated 841 patients receiving either doublet therapy, combining androgen deprivation therapy (ADT) with androgen receptor pathway inhibitors […]

Read more

ARASAFE Trial Offers Safer Docetaxel-Darolutamide-ADT Regimen for mHSPC

/in , , /by

Recent data presented at the 2025 European Society for Medical Oncology (ESMO) Congress reveal a promising new treatment schedule for patients with metastatic hormone-sensitive prostate cancer (mHSPC). The phase 3 ARASAFE trial evaluated an alternative docetaxel dosing regimen combined with darolutamide and androgen deprivation therapy (ADT), showing significant reductions in severe toxicities while maintaining effective […]

Read more

Phase 1/2 PETRANHA Trial Update: Promising Results Reported at ESMO 2025

/in , , , /by

At the 2025 ESMO Congress, new data from the phase 1/2 PETRANHA trial introduced saruparib (AZD5305), a highly selective PARP1 inhibitor, as a potentially safer and more effective therapeutic partner for androgen receptor pathway inhibitors (ARPIs) in metastatic prostate cancer. The results highlighted a strong efficacy signal in castration-sensitive disease and ARPI-naïve castration-resistant settings, while […]

Read more

AI Model Bridges Cellular Biology and Machine Reasoning

/in /by

A collaboration between Yale University and Google DeepMind has led to a rare scientific milestone: an artificial intelligence system that not only analyzed biological data but also generated and experimentally validated a new hypothesis for cancer treatment. Announced on October 15, 2025, the 27‑billion‑parameter foundation model, called Cell2Sentence‑Scale 27B, was developed to interpret single‑cell RNA […]

Read more

Two-Pronged Drug Combination for Advanced Prostate Cancer: Fadraciclib Plus Ipatasertib (or Capivasertib)

/in /by

Scientists at The Institute of Cancer Research in London have identified a combination therapy that may benefit up to 40 percent of men with advanced prostate cancer, particularly those whose tumors have become resistant to hormone therapies. This approach targets two proteins essential for cancer cell survival: MCL1 and AKT. Direct inhibition of MCL1 has […]

Read more

Phase 2: Copper-Based PET Imaging Agent Surpasses Standard Tracer for Early Prostate Cancer Lesion Detection

/in , , /by

The phase 2 Co-PSMA trial conducted at St Vincent’s Hospital in Sydney evaluated 64Cu-SAR-bisPSMA, a novel copper-based PET imaging agent, against the standard 68Ga-PSMA-11 tracer in patients with biochemical recurrence of prostate cancer and low PSA levels. Results showed 64Cu-SAR-bisPSMA detected a statistically greater number of PSMA-positive lesions per patient than the standard agent, particularly […]

Read more

Phase 2 Trial: Optimal PSA-Triggered Intermittent Therapy for mHSPC

/in , , /by

This Phase II study explores a novel approach to treating metastatic hormone-sensitive prostate cancer (mHSPC) through PSA-triggered intermittent therapy. Traditionally, men with mHSPC are managed with continuous androgen deprivation therapy (ADT) in combination with androgen receptor pathway inhibitors (ARPIs). This strategy has significantly extended survival but often leads to enduring side effects such as fatigue, […]

Read more